{"id":2059415,"date":"2023-10-08T00:08:02","date_gmt":"2023-10-08T04:08:02","guid":{"rendered":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/new-study-links-ozempic-and-wegovy-to-serious-gastrointestinal-conditions-stomach-paralysis\/"},"modified":"2023-10-08T00:12:47","modified_gmt":"2023-10-08T04:12:47","slug":"new-study-links-ozempic-and-wegovy-to-serious-gastrointestinal-conditions-stomach-paralysis","status":"publish","type":"post","link":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/new-study-links-ozempic-and-wegovy-to-serious-gastrointestinal-conditions-stomach-paralysis\/","title":{"rendered":"Ozempic and Wegovy tied to severe stomach issues, paralysis."},"content":{"rendered":"<aside class=\"mashsb-container mashsb-main mashsb-stretched\"><div class=\"mashsb-box\"><div class=\"mashsb-count mash-medium\" style=\"&quot;\"><div class=\"counts mashsbcount\">18<\/div><span class=\"mashsb-sharetext\">SHARES<\/span><\/div><div class=\"mashsb-buttons\"><a class=\"mashicon-facebook mash-medium mash-nomargin mashsb-noshadow\" href=\"https:\/\/www.facebook.com\/sharer.php?u=https%3A%2F%2Fwww.conservativenewsdaily.net%2Fbreaking-news%2Fnew-study-links-ozempic-and-wegovy-to-serious-gastrointestinal-conditions-stomach-paralysis%2F\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Facebook<\/span><\/a><a class=\"mashicon-twitter mash-medium mash-nomargin mashsb-noshadow\" href=\"https:\/\/twitter.com\/intent\/tweet?text=&amp;url=https:\/\/www.conservativenewsdaily.net\/breaking-news\/?p=2059415&amp;via=ConservNewsDly\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Twitter<\/span><\/a><a class=\"mashicon-subscribe mash-medium mash-nomargin mashsb-noshadow\" href=\"#\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Subscribe<\/span><\/a><div class=\"onoffswitch2 mash-medium mashsb-noshadow\" style=\"display:none\"><\/div><\/div>\n            <\/div>\n                <div style=\"clear:both\"><\/div><\/aside>\n            <!-- Share buttons by mashshare.net - Version: 4.0.47--><blockquote>\n<h2>Semaglutide: Popular Weight Loss Drugs Linked \u200bto Serious Health Issues<\/h2>\n<p>A new study\u2062 has revealed that \u200csemaglutide, the active ingredient in weight loss \u2062drugs Ozempic and Wegovy, can have detrimental effects on users&#8217; health. These effects include severe \u2063stomach conditions like paralysis and gastroparesis\u2064 in diabetics.<\/p>\n<\/blockquote>\n<p>The drugs\u200d function by mimicking a hormone called Glucagon-like peptide \u20631 (GLP-1), which induces \u2062a feeling of satiety after meals. They are commonly used for weight maintenance and regulate\u2062 appetite, as well as delay gastric emptying and gut motility in humans.<\/p>\n<p>The study, published in JAMA\u200d Network on October 5th, examined the \u2062gastrointestinal adverse events \u200bassociated with GLP-1 agonists. Researchers analyzed health insurance \u200dclaim records of approximately 16 million U.S. patients \u200cwho were prescribed these drugs between\u2063 2006 and 2020. \u2064The study focused on the development of four gastrointestinal conditions\u200d in non-diabetic individuals:<\/p>\n<ul>\n<li>Biliary disease, a group of conditions affecting the gallbladder.<\/li>\n<li>Pancreatitis, inflammation of the pancreas that can lead to severe abdominal \u2063pain and may require hospitalization and surgery.<\/li>\n<li>Bowel obstruction, where food cannot pass through the intestines, causing symptoms such as cramping, nausea, bloating, and vomiting. In severe cases, \u200bsurgery may be\u2064 necessary.<\/li>\n<li>Gastroparesis, \u2062also known as stomach paralysis, which restricts \u200dthe passage of \u200dfood from the \u2062stomach \u200bto the small\u200c intestine and can cause abdominal pain, vomiting, and nausea.<\/li>\n<\/ul>\n<p>The study compared \u2062GLP-1 agonists to the weight loss drug Contrave. It \u2062found that GLP-1\u2064 agonists, including semaglutide, were associated with significantly higher risks of pancreatitis, bowel obstruction, and gastroparesis \u2063compared to Contrave. \u2063The incidence of\u2062 biliary disease was also higher, but the difference was not statistically significant.<\/p>\n<p>Conducted by the University of British Columbia, this research is the first large-scale study to examine adverse gastrointestinal events \u2062in non-diabetic patients using GLP-1 agonists for weight loss. The study&#8217;s findings emphasize the importance of considering\u2062 these rare but serious adverse events when deciding to use these \u2062drugs for weight loss.<\/p>\n<h2>Risk of\u2063 Gastrointestinal Issues<\/h2>\n<p>Initially developed to manage type 2 diabetes, GLP-1 agonists have gained popularity as off-label weight \u200closs medications.\u2064 In 2022 alone, approximately\u200c 40 million prescriptions\u200c for these drugs\u200d were issued in the United States.<\/p>\n<p>While some GLP-1 agonists were only approved for obesity treatment \u2063in 2021,\u200d the initial clinical trials focused\u2062 on their efficacy for weight loss and did not\u200b thoroughly \u200bassess gastrointestinal events associated with their \u200cuse.<\/p>\n<p>The University of \u2064British Columbia researchers aimed to\u200d address this knowledge gap. Although the adverse events measured in the study are rare, they could still\u2063 impact hundreds of thousands of people\u200b due to the widespread use of these drugs.<\/p>\n<p>&#8220;These drugs are becoming increasingly accessible, and it is concerning that people can \u2063simply order \u200cthem online without fully understanding the potential risks. This goes against the principle of informed consent,&#8221; said Mohit\u200d Sodhi, a\u200d graduate of\u2064 UBC&#8217;s experimental medicine \u200dprogram and one of the study&#8217;s authors.<\/p>\n<p>The researchers hope that\u2063 drug regulators and manufacturers will update warning \u200blabels related to GLP-1 agonists to ensure patients \u2064are aware of these risks and can seek timely medical attention if needed.<\/p>\n<p>Both Ozempic and\u2062 Wegovy, the weight loss drugs containing semaglutide, are manufactured by Danish pharmaceutical company Novo Nordisk. \u200bThe company stands by the\u2063 safety and efficacy of their GLP-1RA medicines but acknowledges the potential side effects mentioned in their product monographs.<\/p>\n<h2>FDA&#8217;s List of Risks\u2063 for Ozempic<\/h2>\n<p>The \u200dUBC study coincides with the U.S.\u200b Food and \u2063Drug Administration&#8217;s (FDA) recent update to the safety-related labeling for Ozempic. The FDA \u2063added the gastrointestinal disease &#8220;Ileus&#8221; as an adverse reaction to the drug.<\/p>\n<p>Ileus\u200c is a condition\u200c in which the intestines temporarily lose their ability \u2064to contract, restricting the movement of food\u200d and waste in the body.<\/p>\n<p>According to the FDA&#8217;s Adverse Events Reporting System (FAERS), there have been 14,149 reports of <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/life-threatening-infection-fda-recalls-eye-drops-over-bacterial-fungi-contamination\/\" title=\"FDA recalls eye drops due to bacterial and fungal contamination, posing life-threatening infection risk.\">adverse\u200d events related<\/a> to Ozempic, including 6,253\u2064 serious\u2062 cases and 163 deaths.<\/p>\n<p>The adverse reactions primarily involved gastrointestinal disorders, injury, poisoning, procedural complications, general disorders, and administration site conditions. Other complications such as <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/will-pfizer-be-charged-for-mislabeling-vaccine-side-effects\/\" title=\"Will Pfizer Be Charged for Mislabeling Vaccine Side Effects?\">nervous system disorders<\/a>, metabolism\u2064 and nutrition disorders,\u2063 and \u2064skin and subcutaneous tissue disorders were also reported.<\/p>\n<p>The official Ozempic website warns users about \u2063potential\u2064 serious side\u2063 effects, including inflammation of the pancreas, low blood sugar, changes in vision, serious allergic reactions, kidney issues, and gallbladder problems.<\/p>\n<p>While Ozempic is only approved for type 2 diabetes, Wegovy has been approved by the FDA for obesity treatment. However, both <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/new-study-links-ozempic-and-wegovy-to-serious-gastrointestinal-conditions-stomach-paralysis\/\" title=\"Ozempic and Wegovy tied to severe stomach issues, paralysis.\">drugs share similar potential side effects<\/a>.<\/p>\n<p>As the use of GLP-1 agonists continues to rise, it is crucial\u2063 for \u2062patients\u2062 to be\u2062 fully informed about the \u2063potential risks and \u2063to consult with healthcare providers before starting any medication\u200c regimen.<\/p>\n<p> <\/p>\n<h2> What potential risks are associated with \u2063the use\u2063 of semaglutide and other GLP-1 agonists for weight loss?<\/h2>\n<p><span>  The potential gastrointestinal risks of semaglutide and \u2063other GLP-1 agonists, and that healthcare providers will discuss these risks with their patients before prescribing these medications.<\/p>\n<h2>Implications \u200cfor\u2064 Patient Care\u2062 and Public Health<\/h2>\n<p>The\u200b findings of this\u2062 study have important implications for patient care and public health. As these weight loss drugs become more widely used, it is crucial that healthcare providers are aware\u2064 of the potential risks associated with their use. They should consider these risks when prescribing\u2063 these medications and discuss them with their patients to ensure \u2064they \u2064make informed decisions about their treatment options.<\/p>\n<p>In addition, drug regulators and manufacturers play a key role in ensuring the safety of medication use. \u2063The results of this study suggest that warning labels for semaglutide and other GLP-1 agonists should be\u200b updated to include information about the increased\u2064 risks of pancreatitis, bowel obstruction,\u2064 and gastroparesis. This will enable patients to better understand and weigh the\u2062 potential benefits and risks of these medications before using them.<\/p>\n<p>Furthermore, \u200dpublic health campaigns and educational initiatives should \u2064be developed to\u2063 increase awareness about the potential gastrointestinal risks \u200bof these weight loss drugs. This will help individuals make informed choices about their health and prevent unnecessary harm that may arise from the use of these medications.<\/p>\n<h2>Conclusion<\/h2>\n<p>The study published in \u2062JAMA Network has\u2063 shed light on the serious gastrointestinal risks associated with semaglutide, the active \u2063ingredient in weight loss drugs Ozempic and Wegovy.\u2064 These\u2064 risks include pancreatitis, bowel obstruction, and gastroparesis, \u200cwhich can have severe consequences for patients&#8217; \u2062health. The study highlights the need to consider these adverse events when prescribing these medications and\u200d emphasizes the importance of\u200c updated warning labels and patient education regarding the risks involved.<\/p>\n<p>As the popularity of semaglutide and other GLP-1 agonists for weight loss continues to \u2064grow, \u2064it \u200cis \u2063crucial that patients and healthcare providers\u200d are well-informed about the potential risks and benefits\u200c of these medications. By doing so, \u200cwe can ensure that \u200cpatients receive\u200d the safest and most effective treatments for their weight management\u200c needs while minimizing\u2063 the risks of serious gastrointestinal complications.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Semaglutide, present in weight loss drugs Ozempic and Wegovy, has been linked to adverse health effects like paralysis and gastroparesis in diabetics, as per a recent study. These drugs imitate the hormone GLP-1, inducing a sense of fullness in users.<\/p>\n","protected":false},"author":186,"featured_media":2059416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_mo_disable_npp":"","fifu_image_url":"https:\/\/cndimages.nyc3.digitaloceanspaces.com\/breaking-news\/wp-content\/uploads\/2021\/01\/IMG_2758-scaled-1.jpg","fifu_image_alt":"","footnotes":""},"categories":[543],"tags":[],"class_list":["post-2059415","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-the-epoch-times"],"fifu_image_url":"https:\/\/cndimages.nyc3.digitaloceanspaces.com\/breaking-news\/wp-content\/uploads\/2021\/01\/IMG_2758-scaled-1.jpg","_links":{"self":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts\/2059415","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/users\/186"}],"replies":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/comments?post=2059415"}],"version-history":[{"count":0,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts\/2059415\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/media\/2059416"}],"wp:attachment":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/media?parent=2059415"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/categories?post=2059415"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/tags?post=2059415"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}